Home World News Adjuvant Selpercatinib Prolongs EFS Among Patients with Stage II or IIIA RET... World News Adjuvant Selpercatinib Prolongs EFS Among Patients with Stage II or IIIA RET Fusion-Positive NSCLC By Ogkologos - June 2, 2026 265 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the LIBRETTO-432 study Source RELATED ARTICLESMORE FROM AUTHOR Can ctDNA guide treatment intensification in EGFR mutated non-small cell lung cancer? How to select adjuvant endocrine therapy for postmenopausal women with HR-positive early breast cancer? EMA Recommends Extension of Therapeutic Indications for Abiraterone Acetate MOST POPULAR EMA Recommends Granting a Marketing Authorisation for Erdafitinib July 10, 2024 New ESMO Framework to Resolve Uncertainties About the De-intensification of Cancer... May 9, 2022 ESMO’s Special Consultative Status with United Nations Economic and Social Council... October 10, 2025 GreaterGood’s Mask Donations Are Helping Wildlife Sanctuaries Continue Their Essential Work September 10, 2020 Load more HOT NEWS High Tumour Mutation Burden Fails to Predict Response to Immune Checkpoint... Coffee Shop Owner Learns He Has Terminal Cancer – So Competitor... Stopping TKI Treatment Is Safe, Improves Quality of Life for Some... Opportunity and mentorship: Our new PhD programme aiming to open-up academia...
